Literature DB >> 15340047

RhoE inhibits cell cycle progression and Ras-induced transformation.

Priam Villalonga1, Rosa M Guasch, Kirsi Riento, Anne J Ridley.   

Abstract

Rho GTPases are major regulators of cytoskeletal dynamics, but they also affect cell proliferation, transformation, and oncogenesis. RhoE, a member of the Rnd subfamily that does not detectably hydrolyze GTP, inhibits RhoA/ROCK signaling to promote actin stress fiber and focal adhesion disassembly. We have generated fibroblasts with inducible RhoE expression to investigate the role of RhoE in cell proliferation. RhoE expression induced a loss of stress fibers and cell rounding, but these effects were only transient. RhoE induction inhibited cell proliferation and serum-induced S-phase entry. Neither ROCK nor RhoA inhibition accounted for this response. Consistent with its inhibitory effect on cell cycle progression, RhoE expression was induced by cisplatin, a DNA damage-inducing agent. RhoE-expressing cells failed to accumulate cyclin D1 or p21(cip1) protein or to activate E2F-regulated genes in response to serum, although ERK, PI3-K/Akt, FAK, Rac, and cyclin D1 transcription was activated normally. The expression of proteins that bypass the retinoblastoma (pRb) family cell cycle checkpoint, including human papillomavirus E7, adenovirus E1A, and cyclin E, rescued cell cycle progression in RhoE-expressing cells. RhoE also inhibited Ras- and Raf-induced fibroblast transformation. These results indicate that RhoE inhibits cell cycle progression upstream of the pRb checkpoint.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15340047      PMCID: PMC515038          DOI: 10.1128/MCB.24.18.7829-7840.2004

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  52 in total

Review 1.  Rho family proteins: coordinating cell responses.

Authors:  A J Ridley
Journal:  Trends Cell Biol       Date:  2001-12       Impact factor: 20.808

2.  Timing of cyclin D1 expression within G1 phase is controlled by Rho.

Authors:  C F Welsh; K Roovers; J Villanueva; Y Liu; M A Schwartz; R K Assoian
Journal:  Nat Cell Biol       Date:  2001-11       Impact factor: 28.824

3.  Rho regulates p21(CIP1), cyclin D1, and checkpoint control in mammary epithelial cells.

Authors:  Muriel Liberto; David Cobrinik; Audrey Minden
Journal:  Oncogene       Date:  2002-02-28       Impact factor: 9.867

Review 4.  Rho GTPases in cell biology.

Authors:  Sandrine Etienne-Manneville; Alan Hall
Journal:  Nature       Date:  2002-12-12       Impact factor: 49.962

5.  Prediction of central nervous system embryonal tumour outcome based on gene expression.

Authors:  Scott L Pomeroy; Pablo Tamayo; Michelle Gaasenbeek; Lisa M Sturla; Michael Angelo; Margaret E McLaughlin; John Y H Kim; Liliana C Goumnerova; Peter M Black; Ching Lau; Jeffrey C Allen; David Zagzag; James M Olson; Tom Curran; Cynthia Wetmore; Jaclyn A Biegel; Tomaso Poggio; Shayan Mukherjee; Ryan Rifkin; Andrea Califano; Gustavo Stolovitzky; David N Louis; Jill P Mesirov; Eric S Lander; Todd R Golub
Journal:  Nature       Date:  2002-01-24       Impact factor: 49.962

Review 6.  Rho GTPases in transformation and metastasis.

Authors:  Aron B Jaffe; Alan Hall
Journal:  Adv Cancer Res       Date:  2002       Impact factor: 6.242

7.  Transcriptional activation of cyclin D1 promoter by FAK contributes to cell cycle progression.

Authors:  J Zhao; R Pestell; J L Guan
Journal:  Mol Biol Cell       Date:  2001-12       Impact factor: 4.138

Review 8.  Cycling to cancer with cyclin D1.

Authors:  J Alan Diehl
Journal:  Cancer Biol Ther       Date:  2002 May-Jun       Impact factor: 4.742

9.  Cell cycle inhibition by FoxO forkhead transcription factors involves downregulation of cyclin D.

Authors:  Marc Schmidt; Silvia Fernandez de Mattos; Armando van der Horst; Rob Klompmaker; Geert J P L Kops; Eric W-F Lam; Boudewijn M T Burgering; René H Medema
Journal:  Mol Cell Biol       Date:  2002-11       Impact factor: 4.272

View more
  49 in total

1.  MicroRNA-200b regulates cyclin D1 expression and promotes S-phase entry by targeting RND3 in HeLa cells.

Authors:  Wei Xia; Jie Li; Liucun Chen; Baochun Huang; Shaohua Li; Guang Yang; Hongmei Ding; Fang Wang; Nongle Liu; Qiang Zhao; Tao Fang; Tao Song; Tianyou Wang; Ningsheng Shao
Journal:  Mol Cell Biochem       Date:  2010-08-04       Impact factor: 3.396

Review 2.  Pathophysiological Functions of Rnd3/RhoE.

Authors:  Wei Jie; Kelsey C Andrade; Xi Lin; Xiangsheng Yang; Xiaojing Yue; Jiang Chang
Journal:  Compr Physiol       Date:  2015-12-15       Impact factor: 9.090

Review 3.  Multifaceted role of Rho proteins in angiogenesis.

Authors:  Sofia D Merajver; Saad Z Usmani
Journal:  J Mammary Gland Biol Neoplasia       Date:  2005-10       Impact factor: 2.673

4.  RhoE is a pro-survival p53 target gene that inhibits ROCK I-mediated apoptosis in response to genotoxic stress.

Authors:  Pat P Ongusaha; Hyung-Gu Kim; Sarah A Boswell; Anne J Ridley; Channing J Der; G Paolo Dotto; Young-Bum Kim; Stuart A Aaronson; Sam W Lee
Journal:  Curr Biol       Date:  2006-12-19       Impact factor: 10.834

5.  Gem associates with Ezrin and acts via the Rho-GAP protein Gmip to down-regulate the Rho pathway.

Authors:  Anastassia Hatzoglou; Isabelle Ader; Anne Splingard; James Flanders; Evelyne Saade; Ingrid Leroy; Sabine Traver; Sandra Aresta; Jean de Gunzburg
Journal:  Mol Biol Cell       Date:  2007-01-31       Impact factor: 4.138

6.  The Rho family member RhoE interacts with Skp2 and is degraded at the proteasome during cell cycle progression.

Authors:  Marta Lonjedo; Enric Poch; Enric Mocholí; Marta Hernández-Sánchez; Carmen Ivorra; Thomas F Franke; Rosa M Guasch; Ignacio Pérez-Roger
Journal:  J Biol Chem       Date:  2013-09-17       Impact factor: 5.157

7.  A genomic strategy for the functional validation of colorectal cancer genes identifies potential therapeutic targets.

Authors:  Marian Grade; Amanda B Hummon; Jordi Camps; Georg Emons; Melanie Spitzner; Jochen Gaedcke; Patrick Hoermann; Reinhard Ebner; Heinz Becker; Michael J Difilippantonio; B Michael Ghadimi; Tim Beissbarth; Natasha J Caplen; Thomas Ried
Journal:  Int J Cancer       Date:  2011-03-01       Impact factor: 7.396

8.  Low-dose chemotherapeutic agents regulate small Rho GTPase activity in dendritic cells.

Authors:  Galina V Shurin; Irina L Tourkova; Michael R Shurin
Journal:  J Immunother       Date:  2008-06       Impact factor: 4.456

9.  RhoE inhibits 4E-BP1 phosphorylation and eIF4E function impairing cap-dependent translation.

Authors:  Priam Villalonga; Silvia Fernández de Mattos; Anne J Ridley
Journal:  J Biol Chem       Date:  2009-12-18       Impact factor: 5.157

10.  Small GTPase RhoE/Rnd3 is a critical regulator of Notch1 signaling.

Authors:  Zehua Zhu; Kristina Todorova; Kevin K Lee; Jun Wang; Eunjeong Kwon; Ivan Kehayov; Hyung-Gu Kim; Vihren Kolev; G Paolo Dotto; Sam W Lee; Anna Mandinova
Journal:  Cancer Res       Date:  2014-02-13       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.